Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 8 Recurrence 2 Prostatic Neoplasms 2 Neoplasms, Plasma Cell 2 Neoplasms 2 Smoldering Multiple Myeloma 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms by Histologic Type 1 Multi-centric Castleman's Disease 1 Monoclonal Gammopathy of Undetermined Significance 1 Macular dystrophy, corneal type 1 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 Colorectal Neoplasms 1 Castleman Disease 1 Carcinoma, Renal Cell 1 Burkitt Lymphoma 1

Interventions

tisagenlecleucel 8 Cyclophosphamide 7 fludarabine 5 blinatumomab 5 aflibercept 4 ibrutinib 2 epratuzumab 2 Vincristine 2 Radioimmunodetection 2 Methotrexate 2 MLN 8237 2 Inotuzumab Ozogamicin 2 Dexamethasone 2 tocilizumab 1 tafasitamab 1 siltuximab 1 sepantronium 1 ruxolitinib 1 relatlimab 1 pembrolizumab 1 pegaspargase 1 ontuxizumab 1 obinutuzumab 1 loncastuximab tesirine 1 forodesine 1 fludarabine phosphate 1 fiu protein, E coli 1 exatecan 1 brexucabtagene autoleucel 1 asparaginase erwinia chrysanthemi recombinant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Burkitt Lymphoma × siltuximab × Clear all

NCT07570173 2026-06-05

MK-1045-005

Merck Sharp & Dohme LLC

Phase 2/3 Recruiting

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡